The Kinetix Group and Consulting at McCann Health’s Research Report on Quality Measures for Nonalcoholic Steatohepatitis (NASH) to Be Presented at ISPOR­ 2019

NEW YORK, March 26, 2019 – The Kinetix Group, in partnership with Consulting at McCann Health, has authored a research report that has been accepted to be exhibited as a poster presentation at ISPOR 2019 in New Orleans on May 20, 2019. The report is titled, “Which Outcome & Quality Measures Do Leading KOLs Who Treat Nonalcoholic Steatohepatitis (NASH) Recommend flor Value-Based Contracting Across Multiple Stakeholders?”, and analyzes primary and secondary research, including insights gathered from 12 US key opinion leaders (KOLs).

The Kinetix Group (TKG) partners with the Ochsner Health Network (OHN) to present the Value Summit 2018 on November 29-30 in New Orleans, LA

NEW YORK, October 30, 2018 – The Kinetix Group (TKG) is proud to partner with the Ochsner Health Network (OHN) to present the second-annual Value Summit on November 29-30, 2018 in New Orleans, with support from the American Medical Group Association (AMGA).

The Kinetix Group Partners with Rimidi to Launch a Clinical Care Partnership for the Management of Nonalcoholic Steatohepatitis (NASH)

NEW YORK, August 30, 2018 – The Kinetix Group in partnership with Rimidi, an Atlanta-based health care technology firm, announced a partnership focused on improving Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) care delivery leveraging NASHNET, a global centers of excellence network.

The Nonalcoholic Steatohepatitis (NASH) Network in Collaboration with Echosens Launches a Real World Evidence Model

NEW YORK, August 23, 2018 – The global NASH market is projected to reach $21.5 billion by 2025, with NASH being the leading cause of liver transplantation in the US in the coming years. 1 The NASH Network (NASHNET), in collaboration with The Kinetix Group, has launched a Real World Evidence study to optimize care delivery for patients with Non-Alcoholic Steatohepatitis (NASH).  This initiative is in partnership with Echosens, the innovators and marketers of the FibroScan® family of products.

The Kinetix Group’s Senior VP of Business Development, Merissa Oliver, to speak at the AMCP Managed Care and Specialty Pharmacy Annual Meeting 2018

NEW YORK, March 26, 2018 – At this year’s AMCP Managed Care and Specialty Pharmacy Annual Meeting, The Kinetix Group’s Senior VP of Business Development, Merissa Oliver, will lead the “Real-world initiatives from inside the health care system – How your customers are driving change” panel from 2:15-5:00 pm on Monday, April 23rdas part of the conference’s Corporate Training Program. Participating panelists include the following health system and pharmacy experts:

AMGA-TKG Collaborative Reduces Heart Failure Readmission Rates by 12%

NEW YORK, March 7, 2018 – The Kinetix Group (TKG), a leading life science marketing agency and health system and payer consultancy, partnered with the American Medical Group Association (AMGA) to build the “Best Practices in Managing Patients with Heart Failure (HF) Collaborative,” launched by AMGA in 2015. TKG developed the collaborative alongside a global life science company to establish a forum for health systems and medical groups to increase patient self-management and enhance the patient experience of care. It is TKG’s second collaborative with the AMGA after the implementation of a successful Rheumatoid Arthritis program launched in 2014.

The Kinetix Group (TKG) Supports the AMGA 2018 Annual Conference as a Silver Exhibitor and Premier Corporate Partner

NEW YORK, February 28, 2018 – The Kinetix Group will be joining prominent healthcare thought leaders as a Silver Exhibitor at the AMGA 2018 Annual Conference from March 7th – March 10th, which includes representation from Academic/Faculty Practices, Group Practices, ACOs, and many more healthcare organizations.